Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome

Open access
Belfort, Renata, Berria, Rachele, Cornell, John, Cusi, Kenneth·2010·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist widely used in clinical practice, but its mechanism of action is incompletely understood. OBJECTIVE: The aim of the study was to assess whether improvement in subclinical inflammation or glucose metabolism contributes to its antiatherogenic effects in insulin-resistant subjects with the metabolic syndrome (MetS). DESIGN AND SETTING: We conducted a randomized, double-blind, placebo-controlled study in the research unit at an academic center. PATIENTS: We studied 25 nondiabetic insulin-resistant MetS subjects. INTERVENTION(S): We administered fenofibrate (200 mg/d) and placebo for 12 wk. MAIN OUTCOME MEASURES: Before and after treatment, we measured plasma lipids/apolipoproteins, inflammatory markers (high-sensitivity C-reactive protein, IL-6, intercellular adhesion molecule/vascular cell adhesion molecule), adipocytokines (adiponectin, TNFalpha, leptin), and insulin secretion (oral glucose tolerance test). We also assessed adipose tissue, hepatic and peripheral (muscle) insulin resistance fasting and during a euglycemic insulin clamp with (3)H glucose and (14)C palmitate infusion combined with indirect calorimetry. RESULTS: Subjects displayed severe insulin resistance and systemic inflammation. Fenofibrate significantly reduced plasma triglyceride, apolipoprotein (apo) CII, apo CIII, and apo E (all P < 0.01), with a modest increase in high-density lipoprotein-cholesterol (+12%; P = 0.06). Fenofibrate markedly decreased plasma high-sensitivity C-reactive protein by 49.5 +/- 8% (P = 0.005) and IL-6 by 29.8 +/- 7% (P = 0.03) vs. placebo. However, neither insulin secretion nor adipose tissue, hepatic or muscle insulin sensitivity or glucose/lipid oxidation improved with treatment. Adiponectin and TNF-alpha levels were also unchanged. Improvement in plasma markers of vascular/systemic inflammation was dissociated from changes in triglyceride/high-density lipoprotein-cholesterol, apo CII/CIII, or free fatty acid concentrations or insulin secretion/insulin sensitivity. CONCLUSIONS: In subjects with the MetS, fenofibrate reduces systemic inflammation independent of improvements in lipoprotein metabolism and without changing insulin sensitivity. This suggests a direct peroxisome proliferator-activated receptor alpha-mediated effect of fenofibrate on inflammatory pathways, which may be important for the prevention of CVD in high-risk patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2009-1487

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 26

  1. Cusi, 2001, Cardiovascular risk management in type 2 diabetes: from clinical trials to clinical practice, The Endocrinologist, 11, 474, 10.1097/00019616-200111000-00009 · DOI
  2. Caballero, 2004, Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes, Curr Diab Rep, 4, 237, 10.1007/s11892-004-0074-9 · DOI
  3. Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 · DOI · Paper page
  4. Plutzky, 2007, Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARα, Diab Vasc Dis Res, 4, S12, 10.3132/dvdr.2007.052 · DOI
  5. Shen, 1991, Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 73, 503, 10.1210/jcem-73-3-503 · DOI
  6. Avogaro, 2001, Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients, Eur J Clin Invest, 31, 603, 10.1046/j.1365-2362.2001.00856.x · DOI
  7. Damci, 2003, Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia, Eur J Intern Med, 14, 357, 10.1016/S0953-6205(03)90001-X · doi:10.1016/s0953-6205(03)90001-x
  8. Vuorinen-Markkola, 1993, Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients, Diabetologia, 36, 161, 10.1007/BF00400699 · DOI
  9. Anderlová, 2007, Influence of PPAR-α agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes, Physiol Res, 56, 579, 10.33549/physiolres.931058 · DOI
  10. Abbasi, 2008, Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects, Am J Cardiol, 102, 64, 10.1016/j.amjcard.2008.02.097 · DOI
  11. Ridker, 2001, High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease, Circulation, 103, 1813, 10.1161/01.CIR.103.13.1813 · DOI · Paper page
  12. Staels, 1998, Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators, Nature, 393, 790, 10.1038/31701 · DOI · Paper page
  13. Capell, 2003, Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia, Arterioscler Thromb Vasc Biol, 23, 307, 10.1161/01.ATV.0000046230.02211.B4 · DOI
  14. Rosenson, 2009, Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients, Obesity, 17, 504, 10.1038/oby.2008.530 · DOI
  15. Després, 2009, Bringing JUPITER down to earth, Lancet, 373, 1147, 10.1016/S0140-6736(09)60448-7 · DOI
  16. Chakravarthy, 2005, “New” hepatic fat activates PPARα to maintain glucose, lipid, and cholesterol homeostasis, Cell Metab, 1, 309, 10.1016/j.cmet.2005.04.002 · DOI · Paper page
  17. Haluzik, 2006, Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-α agonist treatment is accompanied by paradoxical increase of circulating resistin levels, Endocrinology, 147, 4517, 10.1210/en.2005-1624 · DOI
  18. Jones, 1990, Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM, Diabetes Care, 13, 855, 10.2337/diacare.13.8.855 · DOI
  19. Kim, 2003, Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis, Diabetes, 52, 1770, 10.2337/diabetes.52.7.1770 · DOI · Paper page
  20. Korenblat, Effects of fenofibrate and long-acting nicotinic acid on intrahepatic triglyceride content and adipose tissue insulin sensitivity in obese human subjects, 10.1016/S0168-8278(09)60059-3 · DOI
  21. Conjeevaram, 2009, A randomized, placebo-controlled study of PPAR-α agonist fenofibrate in patients with nonalcoholic steatohepatitis (NASH), Hepatology, 50, 774A
  22. Vega, 2003, Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome, Clin Pharmacol Ther, 74, 236, 10.1016/S0009-9236(03)00170-X · DOI
  23. Nelson, 2007, Splanchnic spillover of extracellular lipase-generated fatty acids in overweight and obese humans, Diabetes, 56, 2878, 10.2337/db07-0812 · DOI
  24. Vega, 2005, Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia, Am J Cardiol, 95, 1309, 10.1016/j.amjcard.2005.01.073 · DOI
  25. Ridker, 2007, C-reactive protein and the prediction of cardiovascular disease events among those at intermediate risk, J Am Coll Cardiol, 49, 2129, 10.1016/j.jacc.2007.02.052 · DOI · Paper page
  26. Marchesi, 2003, Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia, J Clin Pharm Ther, 28, 419, 10.1046/j.0269-4727.2003.00512.x · DOI

Cited by

See all 159

Metadata

Authors
Belfort, R., Berria, R., Cornell, J., & Cusi, K.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2010-02-01
Volume
95
Issue
2
Pages
829-836
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2159962535
Cited by
159
References
8
FWCI
5.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. https://app.cochat.ai/papers/10.1210/jc.2009-1487
The paper
Belfort, R., Berria, R., Cornell, J., & Cusi, K. (2010). Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-1487

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.